Cargando…

Postmenopausal overactive bladder

Bladder storage symptoms have a severe impact on many areas as regards the quality of life including health-related, social, psychological and working functions. Pharmacotherapy of lower urinary tract stores (LUTS) has been developed to optimize neural control of the lower urinary tract in pathologi...

Descripción completa

Detalles Bibliográficos
Autor principal: Tomaszewski, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352916/
https://www.ncbi.nlm.nih.gov/pubmed/26327873
http://dx.doi.org/10.5114/pm.2014.47984
_version_ 1782360527158116352
author Tomaszewski, Jacek
author_facet Tomaszewski, Jacek
author_sort Tomaszewski, Jacek
collection PubMed
description Bladder storage symptoms have a severe impact on many areas as regards the quality of life including health-related, social, psychological and working functions. Pharmacotherapy of lower urinary tract stores (LUTS) has been developed to optimize neural control of the lower urinary tract in pathologic states. The bladder can be overactive or underactive. Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity, especially in aging population. Therefore, an effective treatment of OAB must result in a meaningful reduction in urinary symptoms. Pharmacotherapy for the OAB must be individualized based on the degree of bother, medication side-effect profile, concomitant comorbidities and current medication regimen. Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB. Alternatively to antimuscarinic therapy, β(3)-adrenergic receptor agonists, due to their efficacy and favorable adverse event profile, are a novel and attractive option of pharmacological treatment of overactive bladder symptoms. A combination of selective antimuscarinic and β(3)-adrenergic receptor agonists, agents with the different mechanism of action, gives a new treatment option for the patient with OAB according to its harms profile. A number of putative novel therapeutic agents is under clinical evaluations that may ultimately provide alternative or combination treatment options for OAB in the nearest future.
format Online
Article
Text
id pubmed-4352916
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-43529162015-08-31 Postmenopausal overactive bladder Tomaszewski, Jacek Prz Menopauzalny Featured Paper Bladder storage symptoms have a severe impact on many areas as regards the quality of life including health-related, social, psychological and working functions. Pharmacotherapy of lower urinary tract stores (LUTS) has been developed to optimize neural control of the lower urinary tract in pathologic states. The bladder can be overactive or underactive. Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity, especially in aging population. Therefore, an effective treatment of OAB must result in a meaningful reduction in urinary symptoms. Pharmacotherapy for the OAB must be individualized based on the degree of bother, medication side-effect profile, concomitant comorbidities and current medication regimen. Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB. Alternatively to antimuscarinic therapy, β(3)-adrenergic receptor agonists, due to their efficacy and favorable adverse event profile, are a novel and attractive option of pharmacological treatment of overactive bladder symptoms. A combination of selective antimuscarinic and β(3)-adrenergic receptor agonists, agents with the different mechanism of action, gives a new treatment option for the patient with OAB according to its harms profile. A number of putative novel therapeutic agents is under clinical evaluations that may ultimately provide alternative or combination treatment options for OAB in the nearest future. Termedia Publishing House 2014-12-30 2014-12 /pmc/articles/PMC4352916/ /pubmed/26327873 http://dx.doi.org/10.5114/pm.2014.47984 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Featured Paper
Tomaszewski, Jacek
Postmenopausal overactive bladder
title Postmenopausal overactive bladder
title_full Postmenopausal overactive bladder
title_fullStr Postmenopausal overactive bladder
title_full_unstemmed Postmenopausal overactive bladder
title_short Postmenopausal overactive bladder
title_sort postmenopausal overactive bladder
topic Featured Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352916/
https://www.ncbi.nlm.nih.gov/pubmed/26327873
http://dx.doi.org/10.5114/pm.2014.47984
work_keys_str_mv AT tomaszewskijacek postmenopausaloveractivebladder